Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2014, Article ID 743634, 10 pages
http://dx.doi.org/10.1155/2014/743634
Research Article

Individually Tailored Screening of Susceptibility to Sarcopenia Using p53 Codon 72 Polymorphism, Phenotypes, and Conventional Risk Factors

1Department of Biomedicine and Prevention, Division of Clinical Nutrition and Nutrigenomics, University of Rome “Tor Vergata”, Via Montpellier 1, 00133 Rome, Italy
2Nuova Clinica Annunziatella, 00147 Roma, Italy
3Department of Surgery and Medical Science, University “Magna Graecia”, 88100 Germaneto, Italy
4Department of Agriculture, University of Naples “Federico II”, 80055 Portici, Italy
5Department of Biology, University of Rome “Tor Vergata”, 00133 Rome, Italy
6CNR, ISN UOS of Pharmacology, Department of Pharmacology, University “Magna Graecia”, 88100 Roccelletta di Borgia, Italy
7National Institute for Mediterranean Diet and Nutrigenomics (I.N.Di.M.), 87032 Amantea, Italy

Received 24 July 2014; Accepted 22 September 2014; Published 13 October 2014

Academic Editor: Stamatios Theocharis

Copyright © 2014 Laura Di Renzo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background and Aim. p53 activity plays a role in muscle homeostasis and skeletal muscle differentiation; all pathways that lead to sarcopenia are related to p53 activities. We investigate the allelic frequency of the TP53 codon 72 in exon 4 polymorphism in the Italian female population and the association with appendicular skeletal muscle mass index in normal weight (NW), normal weight obese (NWO), and preobese-obese (Preob-Ob) subjects. Methods. We evaluated anthropometry, body composition, and p53 polymorphism in 140 women distinguished in NW, NWO, and Preob-Ob. Results. / genotype increases sarcopenia risk up to 20% (/ genotype OR = 1.20; 95% CI = 0.48–2.9; carriers OR = 0.83; 95% CI = 0.83–2.06). The risk of being sarcopenic for / genotype in NWO and Preob-Ob is 31% higher than NW carriers of (RR = 0,31, 95% CI = 0,15–0,66, P = 0,0079). We developed a model able to predict sarcopenia risk based on age, body fat, and p53 polymorphism. Conclusion. Our study evidences that genotyping TP53 polymorphism could be a useful new genetic approach, in association with body composition evaluations, to assess sarcopenia risk.